Teladoc Health Inc. (NYSE: TDOC) closed the day trading at $27.66 up 5.65% from the previous closing price of $26.18. In other words, the price has increased by $+1.48 from its previous closing price. On the day, 4126137 shares were traded. TDOC stock price reached its highest trading level at $27.84 during the session, while it also had its lowest trading level at $25.97.
For a better understanding of TDOC, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.74 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 22.01. For the most recent quarter (mrq), Quick Ratio is recorded 3.00 and its Current Ratio is at 3.10. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.25.
Upgrades & Downgrades
On September 07, 2022, Truist started tracking the stock assigning a Hold rating and target price of $35.Truist initiated its Hold rating on September 07, 2022, with a $35 target price.
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 17 when Trencher Daniel sold 1,000 shares for $26.80 per share. The transaction valued at 26,800 led to the insider holds 21,408 shares of the business.
Trencher Daniel sold 1,000 shares of TDOC for $26,930 on Dec 19. The SVP CORPORATE STRATEGY now owns 22,408 shares after completing the transaction at $26.93 per share. On Dec 01, another insider, Jensen Claus Torp, who serves as the CHIEF INNOVATION OFFICER of the company, sold 1,783 shares for $28.86 each. As a result, the insider received 51,457 and left with 1,782 shares of the company.
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.84 while its Price-to-Book (P/B) ratio in mrq is 0.74.
Stock Price History:
Over the past 52 weeks, TDOC has reached a high of $80.83, while it has fallen to a 52-week low of $21.60. The 50-Day Moving Average of the stock is 26.76, while the 200-Day Moving Average is calculated to be 33.75.
Over the past 3-months, TDOC traded about 4.65M shares per day on average, while over the past 10 days, TDOC traded about 4.8M shares per day. A total of 161.73M shares are outstanding, with a floating share count of 160.19M. Insiders hold about 0.10% of the company’s shares, while institutions hold 83.80% stake in the company. Shares short for TDOC as of Oct 13, 2022 were 33.08M with a Short Ratio of 28.52M, compared to 32.12M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 20.47% and a Short% of Float of 23.33%.
Current recommendations for the stock of the company come from 20 analysts. On average, analysts expect EPS of -$0.25 for the current quarter, with a high estimate of -$0.09 and a low estimate of -$0.65, while EPS last year was -$0.07. The consensus estimate for the next quarter is -$0.41, with high estimates of -$0.19 and low estimates of -$0.62.
Analysts are recommending an EPS of between -$1.59 and -$61.65 for the fiscal current year, implying an average EPS of -$58.74. EPS for the following year is -$1.44, with 24 analysts recommending between -$0.83 and -$2.31.
25 analysts predict $632.59M in revenue for the current quarter. It ranges from a high estimate of $656.99M to a low estimate of $623M. As of the current estimate, Teladoc Health Inc.’s year-ago sales were $554.24M, an estimated increase of 14.10% from the year-ago figure. For the next quarter, 18 analysts are estimating revenue of $655.94M, an increase of 15.30% over than the figure of $14.10% in the same quarter last year. There is a high estimate of $672.47M for the next quarter, whereas the lowest estimate is $641.7M.
A total of 29 analysts have provided revenue estimates for TDOC’s current fiscal year. The highest revenue estimate was $2.43B, while the lowest revenue estimate was $2.39B, resulting in an average revenue estimate of $2.4B. In the same quarter a year ago, actual revenue was $2.03B, up 18.20% from the average estimate. Based on 29 analysts’ estimates, the company’s revenue will be $2.74B in the next fiscal year. The high estimate is $2.9B and the low estimate is $2.65B. The average revenue growth estimate for next year is up 14.20% from the average revenue estimate for this year.